Abstract
Twentyโsix patients with male breast cancer who were admitted to the Center of Oncology and Nuclear Medicine, Istanbul, Turkey, between 1980 and 1988, were analyzed retrospectively. Median age was 60 years. Most lesions were infiltrating ductal carcinomas (92%). Of 26 lesions, 9 were staged as stage II (35%), 14 as stage III (54%), and 3 as stage IV (11%). All but five patients underwent unilateral mastectomy (81%). Postoperative treatment consisted of radiation therapy combined with chemotherapy in 11 patients (42%), chemotherapy with or without hormonal therapy in 4 (15%), radiation therapy alone in 10 (38%). Radiation therapy was delivered for a mean total radiation dose of 52 ยฑ 2 Gy (range 30โ60 Gy). Chemotherapy consisted of cyclophosphamide, methotrexate and 5โfluorouracil (CMF) in most patients (60%). FAC regimen (5โfluorouracil, Adriamycin, and cyclophosphamide) was given to 6 patients (40%). Six patients were known to have died of breast cancer during followโup (23%). Fourteen patients were NED (no evidence of disease) at last followโup (54%). Overall actuarial 5โyear survival was calculated to be 37%, and median actuarial survival was 46.6 months. Actuarial 5โyear diseaseโfree survival was 27%, and median actuarial diseaseโfree survival was 47.1 months. Only one patient had a local recurrence, and eight patients had 13 distant metastases (31%). Age (P = 0.023), tumor stage (P = 0.055) and nodal status (P = 0.013) were the most significant prognostic factors correlated with the overall survival. ยฉ 1993 WileyโLiss, Inc.